Table 5.
Distribution of factors associated with anaemia among study participants
| |
Frequency |
Multivariate analysis |
||
|---|---|---|---|---|
| Anaemic group (n=176) | Non anaemic group (n=176) | aOR (95%CI) | p value | |
|
Variables |
|
|
|
|
|
Gender |
|
|
|
|
| Female |
69 (39.43%) |
83 (47.16%) |
Reference |
|
| Male |
106 (60.57) |
93 (52.84%) |
1.37 [0.82-2.31] |
0.22 |
|
Age group |
|
|
|
|
| 1year |
57 (32.76%) |
8 (4.55%) |
Reference |
|
| [2–4 years] |
89 (51.15%) |
73 (45.48%) |
0.13 [0.05-0.31] |
0.001 |
| [5 – 10 years] |
28 (16.09%) |
95 (53.98) |
0.03 [0.01-0.08] |
0.001 |
|
Access to IPTc drug (SP-AQ) |
|
|
|
|
| No |
87 (49.71%) |
88 (50%) |
Reference |
|
| Yes |
88 (50.29%) |
88 (50%) |
0.78 [0.45-1.33] |
|
|
Stunting |
|
|
|
|
| No |
84 (48%) |
131 (74%) |
Reference |
|
| Yes |
91 (52%) |
45 (25.57%) |
3.37 [1.93-5.88] |
0.001 |
|
Malaria Parasitaemia |
|
|
|
|
| No |
166 (94.86%) |
174 (98.86%) |
Reference |
|
| Yes |
9 (5.14%) |
2 (1.14%) |
5.23 [1.1-28.48] |
0.04 |
|
Sickle cell disorders |
|
|
|
|
| No |
145 (82.86%) |
161 (91.48%) |
Reference |
|
| Yes |
30 (17.14%) |
15 (8.52%) |
2.89 [1.32-6.34] |
0.008 |
|
Alpha Thalassemia |
|
|
|
|
| No |
128 (73.14%9 |
146 (82.95%) |
Reference |
|
| Yes | 47 (28.86%) | 30 (17.05%) | 1.82 [1.2-3.35] | 0.04 |
aOR: adjusted odds ratio. IPTc: Intermittent Preventive Treatment in children. SP-AQ: Sulfadoxine-Pyrimethamine. Goodness-of-fit-test: Hosmer-Lemeshow, Chi2 (8df)=5.07, p=0.75.